Results 41 to 50 of about 3,776 (143)

Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

Pharmaceutics, 2022
Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity ...
Qing Ji, Yuchen Wu, Andreas Albers, Meiyu Fang, Xu Qian   +4 more
doaj   +1 more source

An update on GM-CSF and its potential role in melanoma management

Melanoma Management, 2020
GM-CSF drives the differentiation of granulocytes and monocyte/macrophages from hematopoietic stem cell progenitors. It is required for differentiating monocytes into dendritic cells (DC).
Robert O Dillman
doaj   +1 more source

Oncolytic viruses in melanoma

Frontiers in Bioscience-Landmark, 2022
Malignant melanoma recurrence remains heterogeneous in presentation, ranging from locoregional disease (i.e., local recurrence, satellites, in transit disease) to distant dermal and visceral metastases.
Camille Robinson, Maria M Xu, Smita K Nair, Georgia M Beasley, Kristen E Rhodin   +4 more
doaj   +1 more source

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies

Biomedicines, 2017
Oncolytic virotherapy represents a novel therapeutic strategy in the treatment of gastrointestinal malignancies. Oncolytic viruses, including genetically engineered and naturally occurring viruses, can selectively replicate in and induce tumor cell ...
Daniel H. Ahn, Tanios Bekaii-Saab
doaj   +1 more source

Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages

Cancer Cell International, 2023
Squamous cell carcinomas are the most common head and neck malignancies. Significant progress has been made in standard therapeutic methods combining surgery, radiation, and chemotherapy. Nevertheless, the 5-year survival rate remains at 40–50%.
Hui Dong, Mengli Li, Chen Yang, Wei Wei, Xianglei He, Gang Cheng, Shibing Wang   +6 more
doaj   +1 more source

Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec

, 2018
Objective: Oncolytic immunotherapy involves the use of viruses to target and destroy cancer cells and to induce immune responses for an enhanced antitumor effect.
Erica M. Sommermann, Sandeep Parsad, Robert Nunan, Ali McBride, John Valgus   +4 more
core   +1 more source

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

Molecular Therapy: Oncolytics, 2019
Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly.
Meijun Zheng, Jianhan Huang, Aiping Tong, Hui Yang   +3 more
doaj   +1 more source

Talimogene Laherparepvec Enhances the Efficacy of PD-1 Blockade

, 2017
Talimogene laherparepvec plus pembrolizumab achieved response in 62% of patients with melanoma.

core   +1 more source

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial [PDF]

, 2016
Talimogene laherparepvec is the first oncolytic immunotherapy to receive approval in Europe, the USA and Australia. In the randomized, open-label Phase III OPTiM trial ({"type":"clinical-trial","attrs":{"text":"NCT00769704","term_id":"NCT00769704 ...
Harrington, Kevin J., Kaufman, Howard L., Andtbacka, RH, Downey, Gerald, Harrington, KJ, Szabo, Z, Kaufman, HL, Chen, Lisa, Downey, G, Andtbacka, Robert H. I., Collichio, Frances, Chen, L, Collichio, F, Szabo, Zsolt   +13 more
core   +1 more source

Topical and intralesional therapies for in-transitmelanoma

Melanoma Management, 2019
This report surveys the role of topical and intralesional agents in the management of in-transit melanoma. The extent and progression of in-transit disease is highly variable and many patients can have a protracted period of locoregional control.
Michael A Henderson
doaj   +1 more source